Tango Therapeutics, Inc. (TNGX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Tango Therapeutics, Inc. (TNGX)

Company Performance

Current Price

as of Oct 16, 2024

$7.14

P/E Ratio

N/A

Market Cap

$765.01M

Description

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Metrics

Overview

HQBoston, MA
SectorHealth Technology
IndustryBiotechnology
TickerTNGX
Price$7.14+3.33%

Trading Information

Market Cap$765.01M
Float53.86%
Average Daily Volume (1m)998,893
Average Daily Volume (3m)924,303
EPS-$1.13

Company

Revenue$42.51M
Rev Growth (1yr)36.15%
Net Income-$25.55M
Gross Margin96.82%
EBITDA Margin-145.51%
EBITDA-$28.92M

EV$645.06M
EV/Revenue15.17
P/EN/A
P/S18.19
P/B3.09

Documents

Factset Street Account

Tango Therapeutics to present preclinical data on PRMT5 inhibitors at the Society for Neuro-Oncology Annual Meeting Nov 15-19 ($8.36, 0.00) (2023-11-13T12:13:49Z)

Tango Therapeutics reports Q3 EPS ($0.23) vs FactSet ($0.34) [6 est, ($0.37)-(0.29)] ($8.61, 0.00) (2023-11-08T12:17:50Z)

Tango Therapeutics holder Boxer Capital reports purchase of 1.25M shares -- Form 4/A (17-Oct, post-close) ($7.20, 0.00) (2023-10-18T12:24:25Z)

FDA panel votes that the primary endpoint of CodeBreaK200 can not be reliably interpreted ($264.84, -0.60) (2023-10-05T18:50:34Z)

Amgen presents initial clinical data on its PRMT5 inhibitor AMG 193 -- STAT News ($287.81, +2.77) (2023-10-13T13:54:56Z)

Factset

Factset Business Description